MerLion Pharmaceuticals GmbH

Fonseca Biosciences announced an agreement with MerLion Pharmaceuticals to market XTORO®, an FDA-approved treatment for acute otitis externa caused by Pseudomonas aeruginosa and Staphylococcus aureus. XTORO, with finafloxacin as the active ingredient, offers rapid symptom relief and broad-spectrum microbiological activity. Fonseca plans to distribute XTORO in the US by mid-2025, pending FDA approval of their application.